Dermatitis

Explore some of the key insights from EADV 2023: Prof. Thierry Passeron illuminates pigmentary disorders breakthroughs, Dr Raj Chovatiya unveils atopic dermatitis innovations, Prof. Leonardo Marini sheds light on aesthetic medicine developments, and Prof. Dedee Murrell reveals treatment progress exciting clinical trials and key discoveries in blistering and autoimmune diseases. Filmed in coverage of the EADV Annual Meeting. This content was developed by Touch Medical Media and is not affiliated with the  European Academy of Dermatology & Venereology  (EADV) or the congress. 

A-STAR is the The UK-Irish Atopic Eczema Systemic Therapy Register, an observational study investigating short and long-term safety and efficacy of systemic immuno-modulators for people with atopic dermatitis. The register also assesses the ‘real life’ cost of eczema treatments, comparing therapeutic costs with efficacy. touchDERMATOLOGY caught up with Prof. Carsten Flohr (Guy’s & St Thomas’ NHS Foundation Trust, London, UK) to discuss participants, treatments and outcome measures of the A-STAR register and the comparative efficacy and safety findings. 'Comparing the treatment effectiveness and safety of dupilumab and methotrexate in paediatric and adult atopic dermatitis: results from the A-STAR register' was presented at EADV 2023, Berlin, 11-14 October 2023 #EADVCongress. Questions What impact has dupilumab had on the treatment paradigm for atopic dermatitis since its approval? (0:12) Could you give us a brief overview of the participants, treatments and outcome measures of the A-STAR register? (0:42) What were the aims and design of your analysis of the A-STAR register? (1:09) What were the comparative efficacy and safety findings of your study? (1:57) What were the key take home messages from your study? (2:50) Disclosures: Carsten Flohr has nothing to disclose in relation to this video interview. Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones and Katey Gabrysch. Filmed in coverage of the EADV Annual Meeting. This content was developed by Touch Medical Media and is not affiliated with the  European Academy of Dermatology & Venereology  (EADV) or the congress. 

Atopic march is a concept where the natural progression of atopic dermatitis culminates in allergies including food allergies, conjunctivitis and respiratory allergies, atopic march presents differently amongst patients and the order of progression can vary substantially. touchDERMATOLOGY were delighted to speak with Prof. Carsten Flohr (Guy’s & St Thomas’ NHS Foundation Trust, London, UK) around the progression of atopic march, the associated comorbidities, impact of early detection and prevention strategies on patient outcomes. The presentation 'Early intervention to prevent atopic march?' (Presentation ID D2T02.2A) was presented at EADV 2023, Berlin, 11-14 October 2023 #EADVCongress. Questions Could you describe the progression of atopic march? (0:11) What comorbidities are associated with atopic march? (1:19) What impact is early detection of atopic dermatitis thought to have in the prevention of atopic march? (1:56) What therapies are thought to prevent the development of atopic comorbidities? (3:21) Disclosures: Carsten Flohr has nothing to disclose in relation to this video interview. Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones and Katey Gabrysch. Filmed in coverage of the EADV Annual Meeting. This content was developed by Touch Medical Media and is not affiliated with the  European Academy of Dermatology & Venereology  (EADV) or the congress.  Click here for more content on atopic dermatitis & for further EADV 2023 highlights visit here.

Atopic dermatitis and prurigo nodularis are type 2 inflammatory skin diseases with intense pruritis. Both share mechanisms of disease, including inflammation with the role of type 2 cytokines in driving itch. We were delighted to speak to Expert Faculty member Dr. Raj Chovatiya (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) to discuss the burden of itch and its impact on quality of life, dupilumab’s recent approval and its impact on the treatment landscape. Questions Could you describe the burden of itch and the impact this has on patient quality of life? (0:17) What impact has the approval of dupilumab had on the treatment paradigm for pruritic diseases? (0:56) How do atopic dermatitis (AD) and prurigo nodularis (PN) differ in presentation, despite sharing a similar pathology? (1:29) Aside from relieving itch, what other benefits are associated with targeting IL-4 and IL-13 signalling in AD and PN? (2:13) What are the next steps to achieving disease control in inflammatory skin diseases? (2:42) Disclosures: Raj Chovatiya discloses advising, consulting, and/or speaking for AbbVie, Apogee Therapeutics, Arcutis, Argenx, ASLAN Pharmaceuticals, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant, Eli Lilly and Company, FIDE, Galderma, Genentech, GSK, Incyte, Janssen, LEO Pharma, L’Oréal, Nektar Therapeutics, Opsidio, Pfizer Inc., Regeneron, RAPT, Sanofi, and UCB. Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones and Katey Gabrysch. Filmed in coverage of the EADV Annual Meeting. This content was developed by Touch Medical Media and is not affiliated with the  European Academy of Dermatology & Venereology  (EADV) or the congress. 

Personalised medicine utilises biomarkers to predict patient outcomes and responses to treatment, ensuring that patients get the most effective treatment quicker. We were delighted to speak to Expert Faculty member Dr. William Damsky (Yale School of Medicine, New Haven, CT, USA) around the recent advances made in biomarkers and targeted therapies for inflammatory skin diseases, […]

JADE-EXTEND (NCT03422822) is a phase 3 long-term extension study investigating the efficacy and safety of abrocitinib in atopic dermatitis. In this touchIMMUNOLOGY interview, we caught up with Dr. Melinda Gooderham (SKiN Centre for Dermatology, Ontario, Canada) around her interim analysis of JADE-EXTEND, looking at efficacy by baseline disease severity. The abstract ‘Influence of Baseline Disease […]

Janus kinase inhibitors (JAKis) have transformed the landscape of dermatological therapy over the last 2 years, with six United States Food and Drug Administration approvals and further clinical trials in progress.1 JAKis have proven highly efficacious in dermatological diseases, by blocking the JAK-signal transducer and activator of transcription (STAT) signalling pathway involved in numerous inflammatory […]